Drawing for TWINPIGBIOLAB

USPTO serial 79335334

TWINPIGBIOLAB

Reviewed by CopyMark Law Group

Reg. 7191395Status 700Registered
Filing date
Status date
Registration date
Oct 17, 2023
Examiner
PERKINS, ELLEN J
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with TWINPIGBIOLAB?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Leigh Ann Lindquist

Leigh Ann Lindquist Sughrue Mion, PLLC2000 Pennsylvania Ave. N.W., Suite 9000Washington, DC 20006UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-cancer preparations; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; biopharmaceutical preparations for the treatment of cancer; pharmaceutical products for the treatment of cancer; diagnostic agents for medical purposes; drug delivery agents in the form of dissolvable films, and coating for tablets that facilitate the delivery of pharmaceutical preparations; pharmaceutical drugs for cancer treatment; medicines for human purposes for cancer treatment; pharmaceutical preparations for tumor treatment; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for use in oncology; pharmaceutical diagnostic preparations for medical purposes; ethical medicinal preparations for cancer treatment; pharmaceuticals for the treatment of cancer; non-prescription medicines for intestinal disorders and for the treatment of cardiovascular diseases; biological preparations for the treatment of cancer; pharmaceutical compounds for treating cancerACTIVE—
042Scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; consultancy relating to scientific research in the field of pharmacogenetics; providing medical research information and scientific research information in the field of pharmaceuticals and clinical trials; consultancy relating to pharmaceutical research and development; pharmaceutical research and development; pharmaceutical research services; medical laboratory services; consultancy in laboratory analysis of biology sequence processing for medical research purposes; medical research laboratory services; medical research; analysis and evaluation of medical product development, namely new product testing and design; providing information on the testing, quality evaluation and research of medical products; consultancy in the field of testing, quality evaluation, and research of medical products; scientific research in the fields of medicine, cancerous diseases and pharmacology; research and development of technology for biotechnology; scientific research in the fields of biomedicine; scientific research of biologicsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 5, 2024FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jan 18, 2024FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jan 18, 2024FIMPFINAL DISPOSITION PROCESSED—
Jan 17, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 17, 2023NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 17, 2023R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 3, 2023OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Aug 16, 2023OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 16, 2023OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Aug 14, 2023GPNXNOTIFICATION PROCESSED BY IB—
Aug 1, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 1, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 26, 2023OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 26, 2023OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jul 12, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 23, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 20, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 20, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 20, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 12, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jun 12, 2023ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jun 12, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 12, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 12, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jun 12, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jan 9, 2023RFNTREFUSAL PROCESSED BY IB—
Dec 17, 2022RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Dec 17, 2022RFRRREFUSAL PROCESSED BY MPU—
Oct 7, 2022RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Oct 6, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 28, 2022DOCKASSIGNED TO EXAMINER—
Mar 15, 2022MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 11, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 10, 2022REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance